DESTINY-Breast06

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

DESTINY-Breast06
Dec 29, 2024, 10:16 | Insight
Paolo Tarantino: Top 10 ADC Milestones of 2024
Paolo Tarantino, Clinical Research Fellow at the Dana-Farber Cancer Institute, shared on X: “2024 has…
Dec 12, 2024, 15:40 | Blog
Sara Tolaney: DESTINY-Breast06 - Efficacy by pace of disease progression
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a…
Dec 12, 2024, 08:04 | Insight
Highlights from Day 1 of SABCS 2024 by Sara Tolaney
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Oct 5, 2024, 09:20 | Insight
DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO
ASCO shared a post on X: "Experts Giuseppe Curigliano & Aditya Bardia discuss the results of…
Oct 4, 2024, 17:28 | Blog
Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer
Raffaele Colombo shared a post on X: "sBLA for trastuzumab deruxtecan (T-DXd) has been accepted…
Sep 28, 2024, 14:00 | Blog
Paolo Tarantino: How do the results of DESTINY-Breast06 change our practice?
Paolo Tarantino shared on LinkedIn: "How do the results of DESTINY-Breast06 change our practice? Should…
Jul 9, 2024, 09:41 | Insight
Rebecca Shatsky: Love my good friend Paolo Tarantino’s explanation of Her2 Ultra Low
Rebecca Shatsky shared a post by Paolo Tarantino on X, adding: “Love my good friend Paolo…
Jul 8, 2024, 18:14 | Insight
Paolo Tarantino: What is HER2 « ultralow » breast cancer, and why should you care?
Paolo Tarantino shared on X: “What is HER2 « ultralow » breast cancer, and why…
Jun 22, 2024, 02:02 | Blog
Sameh Abdelmalak: Dr. Giuseppe Curigliano discussing ASCO24 DESTINY-Breast06
Sameh Abdelmalak, Director, Oncology, Educational Partnerships at VuMedi, made the following post on X: "Check out…
Jun 9, 2024, 15:55 | Insight
Chandler Park: Giuseppe Curigliano on sequencing 1st line and beyond Stage IV ER+ breast cancer
Chandler Park recently shared on LinkedIn: “How to sequence treatments for 1st line and beyond…
Jun 5, 2024, 15:22 | Insight
Piotr Wysocki: T-DXd in metastatic ER+/HER2-low breast cancer patients after endocrine treatment failure
Piotr Wysocki recently posted on LinkedIn: "Results of a Destiny-Breast06 trial have been presented by…
Jun 4, 2024, 12:43 | Insight
Chiara Corti: DESTINY-Breast06 results presented by G Curigliano
Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: “DESTINY-Breast06 results…
May 31, 2024, 10:41 | Blog
Jason A. Mouabbi: Here are my anticipated Top 3 breast cancer presentations for ASCO24
Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared a post on X:…
Apr 29, 2024, 15:54 | Insight
Toni Choueiri: Big news to start the day: DESTINY-Breast06 Phase III trial
Toni Choueiri shared on X: "Big news to start the day: DESTINY-Breast06 Phase III trial…
All: 14 Posts: 1 - 100
Special Coverage